Portugal, Spain and the new biotech frontier

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc. We examine the rise of Southern Europe’s biotech ecosystem—from Portugal’s efforts to turn strong science into startups to Spain’s growing depth of capital and talent—and what it will take for the region to compete globally.

Host

⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Hannah Franklin, Associate, Biovance Capital

Pablo Gabriel Cironi Lopez, Director, Life Science Investment, Caixa Capital Risc

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Poddgruvan

Portugal, Spain and the new biotech frontier

Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil

Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water

The Golden Triangle and the gaps: Rethinking UK biotech

AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more

From fragile skin to living medicine: Lessons from RDEB

Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Rethinking hair loss treatment

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

France’s biotech ecosystem: science, capital and scale